STAT3 and lung disorder: The role of hematopoietic stem cell transplantation (HSCT) remains controversial and is typically reserved for patients with severe, progressive pulmonary disease or life-threatening complications, as it does not correct the STAT3 defect in non-hematopoietic tissues and requires careful consideration of risks and benefits (22).